Peroxisome proliferator-activated receptor γ inhibits pulmonary hypertension targeting store-operated calcium entry
- 353 Downloads
In this study, we investigated the role of peroxisome proliferator-activated receptor γ (PPARγ) on store-operated calcium entry (SOCE) and expression of the main store-operated calcium channel (SOCCs) components, canonical transient receptor potential (TRPC) in chronic hypoxia (CH)-induced pulmonary hypertension (CHPH) rat models. Small interfering RNA (siRNA) knockdown and adenoviral overexpression strategies were constructed for loss-of-function and gain-of-function experiments. PPARγ agonist rosiglitazone attenuates the pathogenesis of CHPH and suppresses Hif-1α, TRPC1, TRPC6 expression in the distal pulmonary arteries (PA), and SOCE in freshly isolated rat distal pulmonary arterial smooth muscle cells (PASMCs). By comprehensive use of knockdown and overexpression studies, and bioinformatical analysis of the TRPC gene promoter and luciferase reporter assay, we demonstrated that PPARγ exerts roles of anti-proliferation, anti-migration, and pro-apoptosis in PASMCs, likely by inhibiting the elevated SOCE and TRPC expression. These effects were inhibited under the conditions of hypoxia or Hif-1α accumulation. We also found that under hypoxia, accumulated Hif-1α protein acts as upstream of suppressed PPARγ level; however, targeted PPARγ rescue acts as negative feedback on suppressing Hif-1α level and Hif-1α mediated signaling pathway. PPARγ inhibits CHPH by targeting SOCE and TRPC via inhibiting Hif-1α expression and signaling transduction.
Rosiglitazone protects PH by normalizing RVSP but not right ventricle hypotrophy.
PPARγ inhibits PASMCs proliferation via targeting SOCE and TRPC by suppressing Hif-1α.
PPARγ and Hif-1α share mutual inhibitory regulation in PASMCs.
PPARγ restoration might be a beneficial strategy for PH treatment.
KeywordsPulmonary hypertension PPARγ TRPC Hif-1α
We thank Drs. Qicai Liu and Bing Li for technical assistance and constructive discussion in this study.
This work was supported by NIH (R01-HL093020), National Natural Science Foundation of China (81173112, 81470246, 81170052, 81220108001), Guangdong Natural Science Foundation team (1035101200300000), Guangzhou Department of Education Yangcheng Scholarship (12A001S), Guangzhou Department of Natural Science (2014Y2-00167), and Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2014, W Lu), China.
Conflict of interest
JW initiated and designed the project, analyzed data, and wrote the paper; WL designed the project and edited the paper; YW performed the animal, functional, and molecular experiments; YW, JZ, XY, and JJ performed the molecular experiments; KY and LT edited the paper; YC, QJ, BZ, and XC performed the animal experiments.
- 6.Lin MJ, Leung GP, Zhang WM, Yang XR, Yip KP, Tse CM, Sham JS (2004) Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension. Circ Res 95:496–505CrossRefPubMedGoogle Scholar
- 12.Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, Wick M, Nemenoff RA, Geraci MW, Voelkel NF (2003) Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 92:1162–1169CrossRefPubMedGoogle Scholar
- 22.Wang J, Yang K, Xu L, Zhang Y, Lai N, Jiang H, Zhong N, Ran P, Lu W (2013) Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPARgamma axis. Am J Respir Cell Mol Biol 49:231–240CrossRefPubMedCentralPubMedGoogle Scholar
- 24.Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE (2001) Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21:365–371CrossRefPubMedGoogle Scholar
- 30.Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M, Phipps RP, Sime PJ (2005) PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 288:L1146–L1153CrossRefPubMedGoogle Scholar
- 34.Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C, Tokarska-Schlattner M, Aasum E, Bogdanova A, Perriard E et al (2009) Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab 9:512–524CrossRefPubMedGoogle Scholar
- 35.Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, Lee MK, Kim UH, Lee YC (2006) Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol 118:120–127CrossRefPubMedGoogle Scholar